Robert Michael Floyd - 08 Jun 2021 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Reporting relationship: Chief Operating Officer
Issuer ticker: PCSA
Reported as of: 08 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2021, 17:09:21 UTC
Next SEC filing: 22 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Michael Floyd by Michael B. Kirwan, as Attorney-in-Fact

Key filing fact

Robert Michael Floyd filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 10 Jun 2021.

Key facts

This page summarizes Robert Michael Floyd's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2021, 17:09.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCSA transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +8,127
Change %
Price: $0.000000
Shares after: 8,127
Date: 08 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,127
Exercise price: $0.000000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.